Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Y-mAbs Therapeutics

13/05/2025 14:32

Y-mAbs Therapeutics Inc YMAB.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -15 cents.  The mean expectation of eight analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -25 cents to -18 cents per share.

Revenue rose 4.9% to $20.90 million from a year ago; analysts expected $19.61 million.

Y-mAbs Therapeutics Inc's reported EPS for the quarter was a loss of 12 cents​.

The company reported a quarterly loss of $5.2 million.

Y-mAbs Therapeutics Inc shares had fallen by 8.1% this quarter and lost 48.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 46.9% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $18.00

This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.21
-0.12
Beat
Dec. 31 2024
-0.12
-0.15
Missed
Sep. 30 2024
-0.16
-0.16
Met
Jun. 30 2024
-0.13
-0.21
Missed